A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1654-1664

  Krepstakies, Marcel ^a   Lucifora, Julie ^b   Nagel, Claus Henning ^a   Zeisel, Mirjam B ^c   Holstermann, Barbara ^a   Hohenberg, Heinrich ^a   Kowalski, Ina ^d   Gutsmann, Thomas ^d   Baumert, Thomas F ^c   Brandenburg, Klaus ^d   Hauber, Joachim ^a   Protzer, Ulrike ^b  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYSTEINYLPROPYLALANYLGLUTAMUNYLARGINYLLYSYLGLUTAMYLGLUTAMYLTHREONYLPHENYLALANYLLYSYLLYSYLTROSYLARGINYLALANINE; GLYCYLCYSTEINYLLYSYLLYSYLTYROSYLARGINYLARGINYLPHENYLALANYLARGINYLTRYPTOPHYLLYSYLPHENYLALANYLHYSYLGLYCYLLYSYLPHENYLALANYLTRYPTOPHYLPHENYLALANYLTRYPTOPHYLGLYCINE; GLYCYLLYSYLLYSYLTYROSYLARGINYLARGINYLPHENYLALANYLARGINYLTRYPTOPHYLLYSYLPHENYLALANYLLYSYLPHENYLALANYLARGINYLLYSYLTRYPTOPHYLPHENYLALANYLTRYPTOPHYLPHENYLALANINE; HEPARAN SULFATE; PEP 19-2.5; PEP 19-4; PEPTIDE; SYNTHETIC ANTI LIPOPOLYSACCHARIDE PEPTIDE; SYNTHETIC PEPTIDE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; HEPARITIN SULFATE; HUMANS; LIPOPOLYSACCHARIDES; PEPTIDES; PROTEIN BINDING; VIRUS ATTACHMENT; VIRUS INTERNALIZATION; VIRUSES;

EID: 84861029503     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis273     Document Type: Article

References (42)

1. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-33.
2. De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs 2008; 13:393-416.
3. De Clercq E. Highlights in the discovery of antiviral drugs: a personal retrospective. J Med Chem 2010; 53:1438-50.
4. Richman DD. Antiviral drug resistance. Antiviral Res 2006; 71: 117-21. (Pubitemid 44223755)
5. Colman PM. New antivirals and drug resistance. Annu Rev Biochem 2009; 78:95-118.
6. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007; 6:1001-18. (Pubitemid 350213865)
7. Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008; 14:1357-62.
8. Wolf MC, Freiberg AN, Zhang T, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 2010; 107:3157-62.
9. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002; 99:15655-60. (Pubitemid 35403987)
10. Gutsmann T, Razquin-Olazaran I, Kowalski I, et al. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob Agents Chemother 2010; 54:3817-24.
11. Andra J, Howe J, Garidel P, et al. Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins: thermodynamic, biophysical and microbiological analysis. Biochem J 2007; 406:297-307. (Pubitemid 47310960)
12. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986; 233:215-9.
13. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59:284-91. (Pubitemid 16013975)
14. Geuenich S, Goffinet C, Venzke S, et al. Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. Retrovirology 2008; 5:27.
15. Sodeik B, Ebersold MW, Helenius A. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J Cell Biol 1997; 136:1007-21. (Pubitemid 27131733)
16. Dohner K, Wolfstein A, Prank U, et al. Function of dynein and dynactin in herpes simplex virus capsid transport. Mol Biol Cell 2002; 13:2795-809.
17. Arzberger S, Hosel M, Protzer U. Apoptosis of hepatitis B virusinfected hepatocytes prevents release of infectious virus. J Virol 2010; 84:11994-2001.
18. Quasdorff M, Hosel M, Odenthal M, et al. A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol 2008; 10:1478-90. (Pubitemid 351837268)
19. Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011; 55:996-1003.
20. Zeisel MB, Koutsoudakis G, Schnober EK, et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007; 46:1722-31.
21. Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 2007; 81:588-98. (Pubitemid 46067886)
22. Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virusneutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104:6025-30. (Pubitemid 47175652)
23. Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010; 139:953-64, 964 e1-4.
24. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-905. (Pubitemid 34535213)
25. Aguilar-Cordova E, Chinen J, Donehower L, Lewis DE, Belmont JW. A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. AIDS Res Hum Retroviruses 1994; 10:295-301. (Pubitemid 24116786)
26. Saphire AC, Bobardt MD, Gallay PA. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J 1999; 18:6771-85.
27. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68:729-77. (Pubitemid 29449208)
28. Rider CC, Coombe DR, Harrop HA, et al. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 1994; 33:6974-80. (Pubitemid 24190823)
29. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski HNorcross MA. Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 1995; 69:2233-9.
30. Oh MJ, Akhtar J, Desai P, Shukla D. A role for heparan sulfate in viral surfing. Biochem Biophys Res Commun 2010; 391:176-81.
31. Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J 2009; 276:7228-36.
32. Heldwein EE, Krummenacher C. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 2008; 65:1653-68.
33. Barth H, Schafer C, Adah MI, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278:41003-12. (Pubitemid 37280923)
34. Barth H, Schnober EK, Zhang F, et al. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 2006; 80:10579-90. (Pubitemid 44628904)
35. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007; 46:1759-68.
36. Hösel M, Quasdorff M, Wiegmann K, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50:1773-82.
37. Untergasser A, Zedler U, Langenkamp A, et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 2006; 43:539-47.
38. Fox JL. Antivirals become a broader enterprise. Nat Biotechnol 2007; 25:1395-402. (Pubitemid 350233129)
39. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004; 2:109-22. (Pubitemid 39490065)
40. O'Donnell CD, Kovacs M, Akhtar J, Valyi-Nagy T, Shukla D. Expanding the role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry. Virology 2010; 397:389-98.
41. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 2006; 44:527-35. (Pubitemid 44433708)
42. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455-71. (Pubitemid 351287949)